By

Luke Timmerman

11
Aug
2020

From Rio to Rome: Rosana Kapeller on The Long Run

Today’s guest on The Long Run is Rosana Kapeller. She’s the president and CEO of Cambridge, Mass.-based ROME Therapeutics. ROME aims to discover and develop drugs based on emerging science in what is sometimes called the “repeatome.” These are long repeat stretches of DNA that scientists until recently knew very little about, and still have a lot to learn about...
Read More
9
Jul
2020

Novavax Nabs $1.6B, BD Secures Fast Antigen Test OK, & a Tribute to Tony Fauci

The United States, it pains me to say as a patriotic believer in our Constitutional system and institutions and generally decent and hardworking people, looks like a disaster zone. A tally of 3.1 million COVID-19 cases, 133,000 deaths, and record numbers of new infections adding up every day can shake one’s faith. Confidence in US institutions, and faith in government...
Read More
6
Jul
2020

Writing in the Language of DNA: Kevin Ness on The Long Run

Today’s guest on The Long Run is Kevin Ness. He’s the CEO of Boulder, CO-based Inscripta. This is a startup that calls itself the “digital genome engineering company.” The aspiration, which Inscripta described in a statement last December, was to create: The world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it...
Read More
25
Jun
2020

The Exponential Curves Re-Emerge

The curves are telling the story. They were flat for a while. Now they’re heading up the exponential slope again. Texas, Arizona, Florida – and even California, which did so well for so long – are among the couple dozen states that are beginning to look up at those scary curves of new COVID-19 cases. We still have no idea...
Read More
11
Jun
2020

Inconvenient Truths and Rays of Light

The information world that we built sometimes has a way of distracting us. It downplays and marginalizes what’s important. Not this week. Let’s start with a few timely, inconvenient truths. As of this writing on June 11: The US has 113,865 dead from COVID-19 and counting. 2 million+ confirmed cases. 20,000 new cases adding up every day. 21 states are...
Read More
10
Jun
2020

Fighting COVID-19 & Racism: Andy Plump on The Long Run

Today’s guest on The Long Run is Andrew Plump. Andy is the president of research and development, and a member of the board of directors, at Takeda Pharmaceutical. Takeda doesn’t get a lot of attention in the US, but it’s one of the world’s biggest pharmaceutical companies by revenue, ranking a little behind AbbVie and a little ahead of Bristol-Myers...
Read More
4
Jun
2020

Anger, Pain, and Hope

The emotions this week were especially intense. Anger. Fear. Despair. But there was also hope. That gets me up in the morning. In this slice of America, the biotech industry, many people are mission-driven. People in this industry work every day to improve the human condition by making better medicines. Not everyone feels the full weight, but many in this...
Read More
28
May
2020

The Infodemic Summer

The US death toll from COVID-19 exceeded 100,000 this week. Another 40 million people are unemployed.  We’ve been on this terrible trajectory for what seems like forever, with 20,000 new cases a day and 1,500 or so deaths every day. The New York Times lists 18 states where new cases are increasing and 19 states where cases are decreasing. Memorial...
Read More
26
May
2020

Finding a Path in Biotech Venture Capital: Nina Kjellson on The Long Run

Today’s guest on The Long Run is Nina Kjellson. Nina is a general partner with Canaan Partners on the West Coast. Her investing style leans toward high science, which you can see in portfolio companies like PACT Pharma, a company developing neoantigen targeted T cell therapies for cancer, Tizona Therapeutics, a targeted antibody developer for cancer, and Vineti, a software...
Read More
21
May
2020

A Glimmer of Hope, and a Premature Celebration

We all woke up Monday morning and saw an encouraging headline. Then things started to go downhill. To recap, Moderna, the Cambridge, Mass.-based messenger RNA therapeutics and vaccines company, provided a snapshot of preliminary data from its Phase I trial of a SARS-CoV-2 vaccine candidate, being tested in collaboration with Tony Fauci’s crew at the National Institute of Allergy and...
Read More